What Is Convalescent Plasma Therapy and Why Doctors Feel It May Be Extremely Effective Against The Coronavirus
8Trials are expected in the UK
There are studies and trials that are expected to commence in the UK in the coming weeks where the national blood service in Britain has already started screening blood from patents in hopes to source plasma rich antibodies that can be used in trials. Professor David Tappin, a senior research fellow at the University of Glasgow, has applied to UK’s National Institute for Health Research for permission to conduct two clinical trials using convalescent plasma. They will attempt to find out if the plasma can protect frontline workers and caregivers from the virus including patients from deteriorating further to the point of requiring ventilators to live.
9Doctors in the UK are asking health regulatory bodies to speed up the process
According to a report in the Daily Mail, it mentioned that health regulators revealed that the convalescent plasma therapy was already approved for NHS medics to use in tackling COVID-19. Speaking to reporters Dr. Colin Hamilton-Davies, of Bart’s Hospital in London, told SkyNews: ‘We could be administering it, not just to one or two people, but hundreds of patients. ‘It’s not only myself, but many colleagues are saying “why aren’t we looking at this in greater depth and in a faster timeframe?” ‘There is a research framework which is up and running, which it may or may not become part of. I very much hope it does. This is something we could get up and running very quickly indeed.’
10Caution is needed as the concept is still new
According to Tappin “The outcomes are also encouraging for these patients.” but he also said that further trials are necessary to be absolutely sure that plasma improved the conditions of patients. Professor Munir Pirmohamed, the president of the British Pharmacological Society, also said that caution should be exercised need to be cautious saying that the plasma treatment in Wuhan was used in combination with other drugs and medication. “It is also important to remember that there are potential safety concerns with convalescent plasma, including transmission of other agents and antibody enhancement of disease,” he added. “Even if shown to work, scalability to treat large numbers of patients may become an issue.”